Nisa Investment Advisors
TCRX icon

Nisa Investment Advisors’s TScan Therapeutics TCRX Stock Holding History

Nisa Investment Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-593
Closed -$1.08K – 3080
2025
Q3 		$1.08K Sell
593
-141
-19% -$250 ﹤0.01% 2728
2025
Q2 		$1.06K Buy
734
+382
+109% +$552 ﹤0.01% 2724
2025
Q1 		$486 Buy
352
+292
+487% +$632 ﹤0.01% 2805
2024
Q4 		$182 Sell
60
-61
-50% -$276 ﹤0.01% 2945
2024
Q3 		$603 Buy
+121
New +$730 ﹤0.01% 2689

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Nisa Investment Advisors's TCRX Position: Q4 2025 in Review

Nisa Investment Advisors sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 593 shares — an estimated $1.08K sold.

Nisa Investment Advisors first reported a position in TCRX in Q3 2024 and held it in 5 quarters. The position peaked at $1.08K in Q3 2025. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Nisa Investment Advisors reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 593 TScan Therapeutics shares in Q4 2025, an estimated $1.08K.
  • Nisa Investment Advisors first reported a position in TScan Therapeutics in Q3 2024 and held it in 5 quarters.
  • Nisa Investment Advisors's TScan Therapeutics position peaked at $1.08K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Nisa Investment Advisors's 13F filing for Q4 2025, filed 15 Jan 2026.